GSK to further develop NeuroSearch drug candidate  

2005.03.30
NeuroSearch licence partner GlaxoSmithKline to initiate clinical Phase II studies with NS2359, a NeuroSearch drug candidate for the treatment of depression

NeuroSearch licence partner, Anglo-American medical giant GlaxoSmithKline (GSK) is to initiate clinical Phase II studies with NS2359, a NeuroSearch drug candidate for the treatment of depression. The decision was made following satisfactory completion of the phase I clinical programme. NeuroSearch will consequently receive a milestone payment of DKK 74 mn (USD 13 mn) from GSK due to a development and licence agreement between the two companies.

 

NS2359 is a new compound for the treatment of depression with a triple mode of action involving three neurotransmitters: serotonin, noradreline and dopamine. Clinical studies have shown that in addition to improving symptoms of depression, the new compound also improved cognitive functions such as concentration, attention and memory. If NS2359 is successfully developed and marketed, NeuroSearch will receive sizeable milestone payments and attractive royalties on sales.

 

NeuroSearch is a Danish biopharmaceutical company listed on the Copenhagen Stock Exchange. It has a wide research and development portfolio including compounds for the treatment of Alzheimer's disease, anxiety disorders, cancer, depression, epilepsy, pain and Parkinson's disease. The news is reported by financial daily newspaper Børsen and on NeuroSearch's website.

 

Link > NeuroSearch 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×